The DST Knockout NCI-H1975 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population that disrupts the DST gene in the human NCI-H1975 lung adenocarcinoma epithelial cell line. This polyclonal pool provides a genetically heterogeneous loss-of-function model to investigate dystonin function in a drug-resistant non-small cell lung cancer (NSCLC) context. CRISPR/Cas9-mediated gene editing introduces a spectrum of disruptions across the population, enabling robust assessment of dystonin-dependent phenotypes without the bias of clonal selection.
The NCI-H1975 cell line was originally isolated from the pleural effusion of a non-smoking female patient with lung adenocarcinoma. It harbors an activating EGFR L858R mutation and the secondary T790M resistance mutation, coupled with MET amplification, making it a well-characterized model of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors (TKIs). These genetic features render NCI-H1975 an ideal host for exploring cytoskeletal contributions to oncogenic signaling and drug resistance.
Dystonin, encoded by DST, is a large plakin family cytoskeletal linker protein that crosslinks intermediate filaments, such as keratins and vimentin, with actin filaments and microtubules. Through direct interactions with integrin ??6??4, collagen XVII, plectin, and other hemidesmosomal components, dystonin maintains cytoarchitecture, cell?Cmatrix adhesion, and mechanical integrity. DST is under upstream regulation by RhoA, Rac1, and Cdc42, which govern actin dynamics, as well as by EGFR and MET signaling pathways. Downstream, dystonin influences the phosphorylation of key effectors including PTK2 (FAK), MAPK1 (ERK2), and MAPK8 (JNK), and is essential for focal adhesion assembly and actin stress fiber formation. Disruption of DST thus impairs the structural and signaling networks that underpin integrin-mediated adhesion and mechanotransduction.
In the NCI-H1975 background, DST knockout directly compromises the cytoskeletal scaffold that integrates co-mutated EGFR and MET signaling. Loss of dystonin is expected to attenuate downstream FAK and ERK activation, thereby altering cell adhesion, migration, and invasion??phenotypes critical for tumor progression and drug resistance. The polyclonal knockout pool captures heterogeneous genetic alterations, better reflecting the clonal diversity seen in patient tumors than monoclonal models, and offers a physiologically relevant system. This model is especially suited for dissecting how cytoskeletal disorganization affects tyrosine kinase inhibitor sensitivity and the survival of drug-resistant cells.
Researchers can utilize this polyclonal DST knockout model to study dystonin??s role in NSCLC cell adhesion, migration, and invasion via scratch wound and transwell assays. The cells are amenable to phospho-EGFR, phospho-FAK, and phospho-ERK analysis by western blotting, as well as immunofluorescence visualization of cytoskeletal networks. Co-immunoprecipitation can probe dystonin interactions with integrin ??1, keratin 14, and vimentin, while RNA-seq enables unbiased transcriptomic profiling of pathways dysregulated by DST loss. Drug sensitivity testing with EGFR TKIs facilitates the discovery of cytoskeleton-dependent resistance mechanisms. For further details, contact Ascent Research.
